Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
We leverage the latest research completed by the nationally recognized University of Miami Miller School of Medicine to offer the latest treatments including promising new approaches through clinical trials. Our endocrinologists work closely with surgeons, fertility specialists, oncologists, nuclear medicine specialists, ophthalmologists, dietitians, and other health care professionals to provide complete care.
Thyroid associated ophthalmopathy (TAO) also known as Graves’ orbitopathy or thyroid eye disease is an autoimmune condition that can lead to changes in the appearance of the eye and eyelids, ocular discomfort, double vision, dry eyes and tearing, corneal exposure, and even blindness in some cases. This condition usually occurs in people with hyperthyroidism (overactive thyroid) or a history of hyperthyroidism due to Graves’ disease, but may also occur in patients with hypothyroidism or no known thyroid abnormalities.
Our oculoplastic surgeons evaluate patients with TAO, and have a variety of medical and surgical treatments to address both functional (loss of vision, double vision, extreme eye dryness) and cosmetic aspects of this disease. In addition, our surgeons are conducting ongoing research of TAO aimed at improving treatment for patients.
myBinderRelated Content
-
Glucocorticoid Regimens for Prevention of Graves’ Ophthalmopathy Progression Following Radioiodine Treatment: ...Background: Glucocorticoid (GC) therapy...
-
Radioiodine Therapy for Juvenile Graves’ Disease: A Single Institution Experience in Japan (Poster 317)131I radioiodine therapy (RIT) has been ...
-
Consensus Statement of the European Group on Graves’ Orbitopathy (EUGOGO) on Management of Graves’ Orbit...Graves’ orbitopathy (GO) constitutes a...
-
Roger Dailey, MD, FACSRoger Dailey is Professor of Ophthalmolo...
-
Brian Chuck Tse, MDBrian Chuck Tse is an Assistant Professo...
-
Treatment Choice, Satisfaction and Quality of Life in Patients With Graves’ DiseaseBackground: Thyrotoxicosis, most often ...
-
Successful Re-Administration of Low-Dose of Methimazole (MMI) in Graves’ Disease Patients who Experienced Alle...Objective: When patients with Graves' d...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Facebook
Google